Publications by authors named "V Dubois"
Carbapenem-resistant Pseudomonas aeruginosa is a global public health concern. IMP-13 is a carbapenemase that was described for the first time in 2001 but is often underestimated due to poor hydrolysis of carbapenems and a lack of molecular detection. The aim of this study was to characterize the genetic support of bla in P.
View Article and Find Full Text PDFArticle Synopsis
- In vitro models are crucial for studying biological processes, disease mechanisms, and drug discovery, particularly in the context of kidney function which is vital for drug and toxin elimination.
- There is a significant lack of studies addressing sex differences in kidney function and diseases, despite the known biological disparities between males and females that can affect health outcomes and drug responses.
- This review calls for the incorporation of sex-specific features in kidney in vitro models to enhance understanding of renal mechanisms and improve treatment efficacy and safety.
In this study, we aimed to investigate the current genetic diversity and provide additional insights into the origins of the Algerian population by analyzing the frequencies of HLA -A,-B,-DRB1,-DQB1 alleles and associated haplotypes. We analyzed 1,082 unrelated healthy Algerian individuals, who were potential kidney donors, recruited and assessed in the Immunology Department of CHU Mustapha in Algiers over a 10-year period (2009-2019). HLA genotyping was performed by Polymerase Chain Reaction Sequence Specific Primers (PCR-SSP).
View Article and Find Full Text PDFArticle Synopsis
- * Researchers aimed to determine the role of antibody-dependent cell-mediated cytotoxicity (ADCC) in avelumab's effectiveness and whether variations in the FcγR3A receptor can predict patient responses.
- * Findings confirmed the presence of FcγR3A+ natural killer (NK) cells in PD-L1-expressing GTN, and that avelumab enhances NK cell activity, further suggesting higher affinity FcγR3A variants may
Article Synopsis
- * Analyzed data from 207 eyes over two years showed no significant differences in visual acuity, intraocular pressure, or glaucoma medication use between the two groups, though more cataracts were noted in optometrist-treated eyes.
- * Overall, the study concluded that both optometrists and ophthalmologists have similar SLT treatment outcomes, but ophthalmologist-treated eyes had higher medication use and lower rates of subsequent surgery.